Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Adenocarcinoma of the Prostate, Prostate Cancer

About this trial
This is an interventional treatment trial for Adenocarcinoma of the Prostate focused on measuring Prostate cancer, PSA level, docetaxel, estramustine, hormone therapy, androgen withdrawal
Eligibility Criteria
Inclusion Criteria: Histologically documented adenocarcinoma of the prostate Previous treatment with either radical prostatectomy or radiation therapy Post prostatectomy: PSA rising on at least two successive occasions at least two weeks apart Post radiation therapy alone: PSA has to be rising as documented on two successive occasions at least two weeks apart and also have doubled from the nadir post treatment value ECOG performance status 0-1 ANC > 1,500/mm3 Platelet counts > 100,000/mm3 SGOT and/or SGPT may be up to 2.5 x ULN Exclusion Criteria: Documented local recurrence of prostate cancer or documented metastatic disease History of other malignancy within the last 5 years, other than curatively treated basal cell carcinoma of the skin Medical condition requiring the use of concommitant corticosteroids Active infection Significant cardiac disease, angina pectoris or myocardial infarction within six months Prior chemotherapy including estramustine, suramin Active thrombophlebitis or history of thromboembolic events in the six months preceding study treatment Clinically significant neuropathy Elevated bilirubin above ULN
Sites / Locations
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
- Lahey Clinic-Burlington
- University of Massachusetts Memorial Medical Center-University Campus
- Norris Cotton Cancer Center